Dr. Nan Zhang joined Houston Methodist Research Institute in 2016 where he developed CRISPR and DNAzyme-based strategies to treat neurodegenerative diseases. He has filed a patent on his technologies, served as editor and reviewer for peer-reviewed journals, and worked as consultant with therapeutic companies. Prior to moving to the US, he studied and worked at Imperial College London on in vitro RNA synthesis and repair, transcription regulation, structural elucidation, and artificial amino acid insertion.
Neurodegeneration, CRISPR-Cas, Oligonucleotide therapies, iPSC, DNA damage repair, mitochondrial dysfunction